SI3509624T1 - Postopki detektiranja nevtralizirajočih protiteles proti leptinu - Google Patents

Postopki detektiranja nevtralizirajočih protiteles proti leptinu

Info

Publication number
SI3509624T1
SI3509624T1 SI201731435T SI201731435T SI3509624T1 SI 3509624 T1 SI3509624 T1 SI 3509624T1 SI 201731435 T SI201731435 T SI 201731435T SI 201731435 T SI201731435 T SI 201731435T SI 3509624 T1 SI3509624 T1 SI 3509624T1
Authority
SI
Slovenia
Prior art keywords
methods
neutralizing antibodies
detecting anti
leptin
leptin neutralizing
Prior art date
Application number
SI201731435T
Other languages
English (en)
Inventor
Jeffrey Sailstad
Original Assignee
Amryt Pharmaceuticals, Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amryt Pharmaceuticals, Inc., filed Critical Amryt Pharmaceuticals, Inc.,
Publication of SI3509624T1 publication Critical patent/SI3509624T1/sl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI201731435T 2016-09-12 2017-09-12 Postopki detektiranja nevtralizirajočih protiteles proti leptinu SI3509624T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393632P 2016-09-12 2016-09-12
PCT/US2017/051232 WO2018049424A1 (en) 2016-09-12 2017-09-12 Methods of detecting anti-leptin neutralizing antibodies
EP17849795.4A EP3509624B1 (en) 2016-09-12 2017-09-12 Methods of detecting anti-leptin neutralizing antibodies

Publications (1)

Publication Number Publication Date
SI3509624T1 true SI3509624T1 (sl) 2023-12-29

Family

ID=61559769

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731435T SI3509624T1 (sl) 2016-09-12 2017-09-12 Postopki detektiranja nevtralizirajočih protiteles proti leptinu

Country Status (18)

Country Link
US (3) US10775386B2 (sl)
EP (2) EP3509624B1 (sl)
JP (2) JP7139317B2 (sl)
CN (1) CN110139663B (sl)
BR (1) BR112019004715A2 (sl)
CA (1) CA3036551A1 (sl)
DK (1) DK3509624T3 (sl)
EA (1) EA201990720A1 (sl)
ES (1) ES2959990T3 (sl)
FI (1) FI3509624T3 (sl)
HR (1) HRP20231076T1 (sl)
HU (1) HUE063647T2 (sl)
MX (1) MX2019002818A (sl)
PL (1) PL3509624T3 (sl)
PT (1) PT3509624T (sl)
RS (1) RS64850B1 (sl)
SI (1) SI3509624T1 (sl)
WO (1) WO2018049424A1 (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019002818A (es) 2016-09-12 2019-08-29 Aegerion Pharmaceuticals Inc Metodos para detectar anticuerpos neutralizantes anti-leptina.
CA3104120A1 (en) * 2018-06-16 2019-12-19 Board Of Regents, The University Of Texas System Weight loss regimen
US20210302421A1 (en) * 2018-08-03 2021-09-30 Bristol-Myers Squibb Company Methods for detecting anti-drug antibodies
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996023517A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
EP0832220A1 (en) 1995-06-07 1998-04-01 Amgen Inc. Ob protein compositions and method
EA199800104A1 (ru) 1995-06-30 1998-10-29 Эли Лилли Энд Компани Способ лечения диабета
DK0865294T3 (da) 1995-08-17 2004-06-28 Amgen Inc Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
ES2339846T3 (es) 1995-11-22 2010-05-26 Amgen Inc. Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob.
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
WO1998006752A1 (en) 1996-08-16 1998-02-19 The Rockefeller University A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway
WO1998008512A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
PL332458A1 (en) 1996-09-20 1999-09-13 Hoechst Ag Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii
JP4175668B2 (ja) 1996-12-20 2008-11-05 アムジエン・インコーポレーテツド Ob融合タンパク質組成物および方法
AU7132798A (en) 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
CA2293504A1 (en) 1997-06-06 1998-12-10 Valur Emilsson Use of leptin antagonists for the treatment of diabetes
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
DE69921486T2 (de) 1998-08-10 2006-02-02 Amgen Inc., Thousand Oaks Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PT1151102E (pt) 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
DE60237100D1 (de) 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
WO2004078944A2 (en) * 2003-03-05 2004-09-16 Maine Medical Center Research Institute Thrombin, soluble jaggedi, and trap and growth of stem cells
US7754497B2 (en) * 2003-08-29 2010-07-13 Reverse Proteomics Research Institute Co., Ltd. Method for immobilizing proteins
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7320868B2 (en) * 2004-03-19 2008-01-22 Arieh Gertler Leptin binding domain compositions and methods thereto
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
JP2011503180A (ja) 2007-11-14 2011-01-27 アミリン・ファーマシューティカルズ,インコーポレイテッド 肥満ならびに肥満関連の疾患および障害の処置方法
GB201004058D0 (en) * 2010-03-11 2010-04-28 Consiglio Nazionale Ricerche Diagnostic assay for obesity and related disorders
EP3241558B1 (en) 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
US20130266963A1 (en) * 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
EP2729160B1 (en) 2011-07-08 2019-03-27 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
WO2015066259A1 (en) 2013-10-31 2015-05-07 Regeneron Pharmaceuticals, Inc. Competitive ligand binding assay for detecting neutralizing antibodies
MX2017011009A (es) * 2015-02-27 2017-10-20 Ionis Pharmaceuticals Inc Modulacion de la expresion de apolipoproteina c-iii (apociii) en poblaciones con lipodistrofia.
MX2019002818A (es) 2016-09-12 2019-08-29 Aegerion Pharmaceuticals Inc Metodos para detectar anticuerpos neutralizantes anti-leptina.

Also Published As

Publication number Publication date
MX2019002818A (es) 2019-08-29
HRP20231076T1 (hr) 2023-12-22
CN110139663B (zh) 2024-05-07
JP2022176209A (ja) 2022-11-25
HUE063647T2 (hu) 2024-01-28
WO2018049424A1 (en) 2018-03-15
CN110139663A (zh) 2019-08-16
US20180074073A1 (en) 2018-03-15
JP7139317B2 (ja) 2022-09-20
EP3509624A4 (en) 2020-02-19
ES2959990T3 (es) 2024-02-29
EP3509624B1 (en) 2023-08-09
US20230314447A1 (en) 2023-10-05
EP3509624A1 (en) 2019-07-17
BR112019004715A2 (pt) 2019-07-16
EP4283304A2 (en) 2023-11-29
CA3036551A1 (en) 2018-03-15
FI3509624T3 (fi) 2023-10-18
EP4283304A3 (en) 2024-02-28
EA201990720A1 (ru) 2019-08-30
PT3509624T (pt) 2023-08-28
PL3509624T3 (pl) 2024-03-25
DK3509624T3 (da) 2023-11-13
US20200378988A1 (en) 2020-12-03
JP2019529904A (ja) 2019-10-17
US10775386B2 (en) 2020-09-15
US11709166B2 (en) 2023-07-25
RS64850B1 (sr) 2023-12-29

Similar Documents

Publication Publication Date Title
HK1254198A1 (zh) 抗-vegf抗體的優化的變體
HK1246324A1 (zh) 抗pd-l1抗體
IL286853B (en) Methods for diagnosing sepsis
SG11201703756RA (en) Determining timing for determination of applicable geo-fences
ZA202002137B (en) Methods of detecting transthyretin
HUE050726T2 (hu) Génsebészeti eljárással bejuttatott ciszteint tartalmazó ellenanyagok szelektív redukálása
HK1243489A1 (zh) 用於檢測分析物的方法和系統
HK1244445A1 (zh) 使用抗-ang2抗體的方法
GB201515693D0 (en) Method for antigen detection
PL3509624T3 (pl) Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie
GB201617628D0 (en) Method of determining presence of Isotopes
PL3589742T3 (pl) Sposób wykrywania
GB201518675D0 (en) Detection of structural forms of proteins
IL247270B (en) A method for detecting cancer
SG11201704642WA (en) Method for the detection of hormone sensitive disease progression
GB2553103B (en) Method of angle detection
GB2553005B (en) Method of line detection
GB201402195D0 (en) Method and systejm for determining spatial position of receiving device
SG10201603579PA (en) Methods Of Detecting Cancer
GB201604600D0 (en) Determination of relative sensitivities
GB201420375D0 (en) Method of detecting amp
GB201514191D0 (en) Method for analyte detection
GB201408537D0 (en) Means and method for detection of analytes